Is Retatrutide More Expensive Than Tirzepatide in the UK?

You have read the headlines, but retatrutide has no price yet

It is entirely reasonable to be excited by the retatrutide data, and slightly frustrated that the news cycle moves faster than the regulatory process. Phase 2 trial results published in 2023 showed substantial average weight reductions (figures that made headlines across the UK press) but a phase 2 result is a long way from a shelf price at a GPhC-registered pharmacy. Eli Lilly, which is developing retatrutide, has not announced a UK list price, because there is no UK licence to attach one to. NICE has not begun an appraisal. The NHS has not issued commissioning guidance.

In practical terms, that means any website quoting a retatrutide price in pounds is speculating, or worse. Until a medicine clears the MHRA's approval process and a manufacturer submits a cost-effectiveness case to NICE, pricing in the UK is genuinely unknown. Comparing a theoretical number with tirzepatide's current private-market cost would not tell you anything useful.

If you want to understand how tirzepatide is priced today and why private costs vary between providers, our page on why Mounjaro costs what it does sets out the factors clearly.

What drives the price of a new weight-loss medicine in the UK

When retatrutide does reach the UK market, its cost will be shaped by several forces that have nothing to do with how effective the medicine is. Manufacturing complexity matters: retatrutide is a triple agonist, activating GIP, GLP-1 and glucagon receptors simultaneously, and producing that molecular structure at scale is more involved than manufacturing a dual agonist. Tirzepatide itself was more expensive at launch than older GLP-1 medicines, partly for that reason.

NICE's cost-effectiveness threshold will then determine whether the NHS funds it at all, and at what list price a deal becomes viable. Eli Lilly raised Mounjaro's UK list price significantly from September 2025 (the highest-dose pen rose from around £122 to around £330) so it would be unwise to assume a newer, more complex molecule would sit below that. Private prices in the UK market since that change have typically ranged roughly £149 to £375 a month depending on the dose and provider, as widely reported.

Triple-agonist chemistry, if it delivers meaningfully better outcomes, may command a premium. Or NICE may negotiate a managed-access scheme that keeps NHS costs contained while private prices remain higher. Nobody outside Eli Lilly's commercial team knows yet. Our overview of how retatrutide compares to Mounjaro covers the clinical distinctions in more detail.

How tirzepatide's cost today compares with what retatrutide might offer

SURMOUNT-1, the pivotal tirzepatide trial published in the New England Journal of Medicine, reported average body-weight reductions of around 20 to 21 percent at the 15 mg dose over 72 weeks. That is a meaningful result; NICE recommended tirzepatide for NHS use in December 2024 on the back of it. Early retatrutide data suggests the potential for higher average reductions, but phase 2 trials use smaller populations and tighter protocols than the phase 3 studies that regulators actually rely on. The final phase 3 picture may look different.

The honest answer is that paying more for a newer medicine only makes sense when that medicine is available, licensed and appropriate for you specifically. Right now, that medicine is tirzepatide. You can read about whether retatrutide is more effective than tirzepatide based on current evidence, and separately consider whether tirzepatide suits your situation now rather than waiting for an unlicensed alternative.

Cost-effectiveness for a prescription medicine is not just the monthly price. Clinical oversight, a genuine UK supply chain, and a prescriber who knows your full health picture all matter. NICE's own appraisal of tirzepatide under TA1026 weighed exactly those factors before recommending it for NHS use. Retatrutide will face the same scrutiny when the time comes.

What to do if you are waiting for retatrutide but need support now

Some people are holding off starting any treatment because they want to wait for retatrutide. That is a personal decision, and there is no right or wrong answer. But weight management is a health question, not a technology upgrade. Waiting an unknown number of years for a medicine that has not yet received a licence (and whose eventual UK price is genuinely unpredictable) carries its own costs in terms of health and wellbeing.

If tirzepatide meets your clinical profile today, a prescriber can assess you properly and, if suitable, you could begin a treatment that already has strong evidence behind it. Our page on Mounjaro in the UK covers everything you need to know about the licensed medicine, and if price is a key concern, this page on Mounjaro costs sets out what a legitimate private prescription realistically involves. For a broader look at licensed weight-loss treatments available right now, our treatment overview is a good starting point.

Speak to our prescribers if you want to talk through your options, the consultation is free, reviewed the same day by a real clinician, and carries no obligation.